Factor 8 Hemlibra denied as non-formulary by Aetna?

Aetna's specific coverage criteria for factor 8 hemlibra are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Hemlibra as Non-Formulary — and Why You Can Appeal

Hemlibra (emicizumab-kxwh) may not appear on every Aetna formulary tier, or may be placed on a tier that requires step therapy or prior authorization before coverage is granted. A non-formulary denial means the plan's benefit design does not include the drug at the tier requested — it is not a clinical determination that the therapy is inappropriate. For a condition as serious as hemophilia A, formulary exceptions are a well-established and frequently successful appeal pathway.

## Why This Denial Is Appealable

Most Aetna plans include a formulary exception process. A formulary exception succeeds when (a) every formulary alternative is contraindicated, has been tried and has failed, or would cause an adverse outcome for this specific patient, or (b) the patient's condition is unique and requires the non-formulary drug. Because hemophilia A with inhibitors may have very few effective alternatives, this is a strong basis for an exception request.

## Federal Appeal Framework

• ERISA §503 (self-funded plans): Full-and-fair review of the formulary exception denial; 180 days to file internally.
• ACA §2719 (fully-insured plans): Independent external review after exhausting internal appeals; typically within four months of the final internal denial.
• Expedited review: Available when a standard timeline would seriously jeopardize health or function; generally resolved within 72 hours.

## Concrete Appeal Steps and Timeline

1. Confirm the denial is a formulary/tier exclusion, not a separate clinical denial. 2. Request the current Aetna formulary and identify any listed alternatives for hemophilia A. 3. For each formulary alternative, document why it cannot be used for this patient. 4. Submit a formulary exception request combined with a medical-necessity appeal. 5. If denied internally, file for external review within four months.

## Documentation to Gather

• Diagnosis confirmation: Specialist-confirmed hemophilia A diagnosis with inhibitor status.
• Formulary alternative assessment: For each drug Aetna lists as a formulary substitute, a prescriber statement explaining why it is clinically inappropriate for this patient — inhibitor presence, prior failure, or contraindication per the FDA-approved prescribing information for that alternative.
• Treatment history: Prior therapy dates, products, outcomes, and any adverse events.
• Prescriber letter: The hematologist should request the formulary exception, state why Hemlibra is medically necessary and no formulary alternative is appropriate, and reference the applicable clinical guideline organization (e.g., ASH or WFH) without asserting specific numeric criteria.
• Clinical severity: Bleed frequency, joint damage records, impact on daily function.

## Criteria-Mapping Structure

Obtain Aetna's formulary exception criteria from the plan documents. Map each criterion to the chart evidence. The most persuasive formulary exception appeals are clinically specific: they do not just say alternatives have failed generically, but identify the specific product, the date of use, and the documented outcome that renders it inadequate for this patient.